Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Owing to the growing number of start-ups that are engaged in R&D of novel biologics, there is significant opportunity for the CMOs in this domain. It is worth highlighting that, since 2000, more than 115 new CMOs have been established in order to cater to the growing demand for novel biologics that have specific manufacturing requirements.

I have highlighted below some of the most interesting insights from our study. You can also access additional details here.


Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages


Eminent representatives from prominent biopharma companies confirm the importance of CMOs, highlighting prevalent and anticipated trends within this domain


Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products


The market landscape is highly fragmented featuring the presence of both established players and new entrants; majority of biopharmaceutical CMOs are based in the developed geographies


Case Study: CMOs focusing on niche biologic markets, primarily novel product candidates for which in-house biomanufacturing expertise is low, are likely to experience significant growth in the coming years


The installed global contract manufacturing capacity, spread across various geographies, is currently estimated to be over 4.5 million liters


The demand for contract manufacturing services is expected to rise across different therapeutic areas; closer inspection of available capacity and expected utilization trend are required to optimize supply parameters


With over 450 deals inked in the past six years, there has been a surge in the partnership activity; majority of the collaborations have been signed for development and manufacturing of cell therapies and antibodies


In order to cater to the increasing demand for biologics, stakeholders are actively expanding their existing capabilities; this is evident from the various acquisitions that have recently been reported


We expect the developers to continue to outsource their manufacturing operations in the short to mid term, resulting in an annualized growth rate of more than 8%


In the long-term, the projected opportunity is anticipated to be well distributed across various types of expression systems used for biomanufacturing, scale of operation and size of contract service providers


To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com. Alternatively, you can place an Order by filling this Order Form.